Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells

Molecular Carcinogenesis

Volumn 54, Issue 12, 2015, Pages 1529-1540

  Gwak, Hyeran ^a,b   Haegeman, Guy ^b   Tsang, Benjamin K ^a,c,d   Song, Yong Sang ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Akt; Glucose metabolism; GLUT1; Ovarian cancer; Resveratrol

Indexed keywords

GLUCOSE TRANSPORTER 1; MESSENGER RNA; PROTEIN KINASE B; PROTEIN P53; RESVERATROL; GLUCOSE; SLC2A1 PROTEIN, HUMAN; STILBENE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL MEMBRANE; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; EPITHELIAL CELLS; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; OVARIAN NEOPLASMS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84944574056     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22227     Document Type: Article

References (38)

1. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 2009; 9:415-428.
2. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9:167-181.
3. Vander Heiden MG. Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 2011; 10:671-684.
4. Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer cell 2012; 21:297-308.
5. Chung HH, Kwon HW, Kang KW, et al. Preoperative [F-18]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. J Gynecol Oncol 2012; 23:28-34.
6. Jung G, Lee Y, Oh S, et al. Comparison of 18F-FDG PET/CT and CT or MRI for the preoperative staging of ovarian cancer. Am J Roentgenol 2007; 188.
7. Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004; 109:926-932.
8. Semaan A, Munkarah AR, Arabi H, et al. Expression of GLUT-1 in epithelial ovarian carcinoma: Correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol 2011; 121:181-186.
9. Lamkin DM, Spitz DR, Shahzad MM, et al. Glucose as a prognostic factor in ovarian carcinoma. Cancer Am Cancer Soc 2009; 115:1021-1027.
10. Kellenberger LD, Bruin JE, Greenaway J, et al. The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol 2010; 2010:514310.
11. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives. Cancer Lett 2008; 269:243-261.
12. Kueck A, Opipari AW Jr, Griffith KA, et al. Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol 2007; 107:450-457.
13. Opipari AW. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004; 64:696-703.
14. Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 2006; 1:2643-2649.
15. Millon SR, Ostrander JH, Brown JQ, Raheja A, Seewaldt VL, Ramanujam N. Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines. Breast Cancer Res Treat 2011; 126:55-62.
16. Rumsey SC, Kwon O, Xu GW, Burant CF, Simpson I, Levine M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem 1997; 272:18982-18989.
17. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1 alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22:7004-7014.
18. Tsuruda T, Hatakeyama K, Nagamachi S, et al. Inhibition of development of abdominal aortic aneurysm by glycolysis restriction. Arterioscl Throm Vas 2012; 32:1410-
19. Li LF, Zhou SH, Zhao K, et al. Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother Radio 2008; 23:701-7714.
20. Montel-Hagen A, Blanc L, Boyer-Clavel M, et al. The Glut1 and Glut4 glucose transporters are differentially expressed during perinatal and postnatal erythropoiesis. Blood 2008; 112:4729-4738.
21. Kim SH, Kim SH, Kim YB, Jeon YT, Lee SC, Song YS. Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells. Ann N Y Acad Sci 2009; 1171:495-500.
22. Hwang SO, Lee GM. Effect of Akt overexpression on programmed cell death in antibody-producing Chinese hamster ovary cells. J Biotechnol 2009; 139:89-94.
23. Wood TE, Dalili S, Simpson CD, et al. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther 2008; 7:3546-3555.
24. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11:85-95.
25. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674.
26. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4:e532.
27. Teiten MH, Mack F, Debbab A, et al. Anticancer effect of altersolanol A, a metabolite produced by the endophytic fungus stemphylium globuliferum, mediated by its pro-apoptotic and anti-invasive potential via the inhibition of NF-kappa B activity. Bioorgan Med Chem 2013; 21:3850-3858.
28. Carden CP, Stewart A, Thavasu P, et al. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther 2012; 11:1609-1617.
29. No JH, Jeon YT, Park IA, et al. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol Oncol 2011; 121:8-12.
30. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 2007; 18:1437-1446.
31. Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 2008; 111:2101-2111.
32. Buller CL, Loberg RD, Fan MH, et al. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Ph 2008; 295:C836-C843.
33. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: Additional value for diagnostic Imaging and patient management. J Nucl Med 2003; 44:1200-1209.
34. Rudlowski C, Moser M, Becker AJ, et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 2004; 66:404-410.
35. Suh DH, Kim MA, Kim H, et al. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med 2014; 14:345-353.
36. Flavahan WA, Wu QL, Hitomi M, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 2013; 16:1373-1385.
37. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010; 10:267-277.
38. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: Current clinical perspectives and future potential. Clin Cancer Res 2013; 19:961-968.